The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
Row over apparent threat to security co-operation with the EU unless it agrees to a trade deal is a "misunderstanding", a minister has said.
The north and west of the country will see rain, while southern and eastern areas will get warm sunshine.
Ministers say the Great Repeal Bill will avoid a "black hole" in the UK's law when we leave the EU. Details are to be published on Thursday.